MMDPPA | CAS# 858215-05-1 | Biochemical

MedKoo Cat#: 576973 | Name: MMDPPA

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MMDPPA is a biochemical categorized as an amphetamine. MMDPPA is a precursor in the synthesis of MDA. (RESEARCH USE ONLY)

Chemical Structure

MMDPPA

CAS#858215-05-1

Theoretical Analysis

MedKoo Cat#: 576973

Name: MMDPPA

CAS#: 858215-05-1

Chemical Formula: C11H13NO3

Exact Mass: 207.0895

Molecular Weight: 207.23

Elemental Analysis: C, 63.76; H, 6.32; N, 6.76; O, 23.16

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 350.00	2 Weeks
5mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MMDPPA; MDA 2-amido analog

IUPAC/Chemical Name

3-(benzo[d][1,3]dioxol-5-yl)-2-methylpropanamide

InChi Key

WJHISTBMGKCBDJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H13NO3/c1-7(11(12)13)4-8-2-3-9-10(5-8)15-6-14-9/h2-3,5,7H,4,6H2,1H3,(H2,12,13)

SMILES Code

CC(C(N)=O)CC1=CC(OCO2)=C2C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

MMDPPA is a biochemical categorized as an amphetamine.

In vitro activity:

An unknown compound from a putative clandestine laboratory was analyzed by GC-MS, GC-IRD, IR (ATR), and NMR and found to be α-methyl-3,4-methylenedioxyphenylpropionamide (MMDPPA), an unusual precursor for the synthesis of 3,4-methylenedioxyamphetamine (MDA), a Schedule I controlled substance. A portion of this precursor was subjected to the Hofmann Degradation (i.e., Hofmann Rearrangement) reaction using a sodium hypochlorite solution (bleach) to produce the expected compound, MDA. Reference: Forensic Sci Int. 2012 Nov 30;223(1-3):279-91. https://pubmed.ncbi.nlm.nih.gov/23116634/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	144.77
	DMSO	25.0	120.64
	Ethanol	10.0	48.26
	PBS (pH 7.2)	0.2	0.97

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 207.23 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

Dal Cason TA, Corbett CA, Poole PK, de Haseth JA, Gouldthorpe DK. An unusual clandestine laboratory synthesis of 3,4-methylenedioxyamphetamine (MDA). Forensic Sci Int. 2012 Nov 30;223(1-3):279-91. doi: 10.1016/j.forsciint.2012.10.002. Epub 2012 Oct 30. PMID: 23116634.

In vitro protocol:

In vivo protocol:

TBD

1. Haarberg, H.E., Paraiso, K.H.T., Wood, E., et al. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol. Cancer Ther. 12(6), 901-912 (2013).